The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Abstract
Purpose: In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%. We aimed to improve these results using more intensive chemotherapy. Patients and Methods: Patients with newly diagnosed early unfavorable HL were randomly assigned to either four cycles of ABVD or an intensified treatment consisting of two cycles of escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by two cycles of ABVD (2 + 2). Chemotherapy was followed by 30 Gy IFRT in both arms. The primary end point was freedom from treatment failure (FFTF); secondary end points included progression-free survival (PFS) and treatment-related toxicity. Results: With a total of 1,528 qualified patients included, the 2 + 2 regimen demonstrated superior FFTF compared with four cycles of ABVD (P < .001; hazard ratio, 0.44; 95% CI, 0.30 to 0.66), with a difference of 7.2% at 5 years (95% CI, 3.8 to 10.5). The difference in 5-year PFS was 6.2% (95% CI, 3.0% to 9.5%). There was more acute toxicity associated with 2 + 2 than with ABVD, but there were no overall differences in treatment-related mortality or secondary malignancies. Conclusion: Intensified chemotherapy with two cycles of BEACOPP escalated followed by two cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
Self-citationDiehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Self-citationHutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Dühmke, E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.023 · Cited by 460
Self-citationChemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064601 · Cited by 450
Interim Analyses: The Repeated Confidence Interval Approach
Jennison, C., & Turnbull, B. W. (1989) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1989.tb01433.x · Cited by 244
Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., Zijlstra, J. M., Bockisch, A., et al. (2008) · Blood · doi:10.1182/blood-2008-06-155820 · Cited by 204
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6394 · Cited by 542
Hodgkin lymphoma: A review and update on recent progress
Shanbhag, S., & Ambinder, R. F. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21438 · Cited by 481
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Engert, A., André, M., Federico, M., Illidge, T., Hutchings, M., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu181 · Cited by 474
Self-citation
Metadata
- Authors
- von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., Zijlstra, J. M., Soekler, M., Stein, H., Eich, H. T., Mueller, R. P., Diehl, V., Borchmann, P., & Engert, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-03-20
- Volume
- 30
- Issue
- 9
- Pages
- 907-913
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127055058
- Cited by
- 314
- References
- 13
- FWCI
- 17.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. https://app.cochat.ai/papers/10.1200/jco.2011.38.5807
- The paper
- von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., Zijlstra, J. M., Soekler, M., Stein, H., Eich, H. T., Mueller, R. P., Diehl, V., Borchmann, P., & Engert, A. (2012). Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.5807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.